Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1523- Ba,    Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression
- in-vitro, OS, MG63 - in-vitro, Nor, hFOB1.19
TumCD↑, Apoptosis↑, ROS↑, eff↓, Casp3↑, Bcl-2↓, selectivity↑, Cyt‑c↑, LDH?, BNIP3?, BAX↑,
1522- Ba,    Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production
- in-vitro, Nor, RAW264.7
*p‑STAT1↓, *p‑STAT3↓, *p‑JAK1↓, *p‑JAK2↓, *iNOS↓, *NO↓, *IL1β↓, *IL6↓, *TNF-α↓, *ROS↓,
1521- Ba,    Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells
- in-vitro, Bladder, 5637
TumCG↓, Apoptosis↑, IAP1↓, IAP2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, MMP↓, Casp8↑, BID↑, ROS?, eff↓, DR4↑, DR5↑, FasL↑, TRAIL↑,
1520- Ba,    Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, TOV-21G
TumCG↓, TumCCA↑, ROS↑, DNAdam↑, Chk2↑, Dose∅, p‑γH2AX↑, CDC25↓, CHK1↓, cycD1/CCND1↓, eff↓, 12LOX↓,
1519- Ba,    Baicalein inhibits KB oral cancer cells by inducing apoptosis via modulation of ROS
- in-vitro, Oral, KB
Apoptosis↑, Dose∅, ROS↑,
1242- BBM,    Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways
- in-vivo, Nor, NA
*Macrophages↓, *Neut↓, *p‑NF-kB↓, *p‑MAPK↓, *p‑JNK↓, *p‑ERK↓,
5554- BBM,  SRF,    Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
ChemoSen↑, STAT3↓,
5536- BBM,    Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers
- Review, Var, NA
JAK↝, STAT3↓, p‑CaMKII ↓, TGF-β↑, Smad1↑, ChemoSen↑, RadioS↑, TumCI↓, TumCMig↓, ROS↑, NRF2↓, SOD2↓, GPx1↓, HO-1↓,
5537- BBM,    CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine
- in-vitro, CLL, NA
CaMKII ↓, NF-kB↓, IKKα↓, p‑STAT3↓,
5538- BBM,    Stabilization of the c-Myc protein by CAMKIIγ promotes T cell lymphoma
- Review, lymphoma, NA
CaMKII ↓, cMyc↝,
5539- BBM,    Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway
- vitro+vivo, CRC, SW480
tumCV↓, TumCCA↑, MMP↓, P53↑, Casp3↑, Casp9↑, BAX↑, PARP↑, Bcl-2↓, TumVol↑,
5540- BBM,    Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCI↓, PI3K↓, Akt↓, MDM2↓, TumCP↓, TumMeta↓,
5541- BBM,    Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, TumCCA↑, Apoptosis↑, BRD4↓, selectivity↑, TumCG↓, cMyc↓,
5542- BBM,    Pharmacological profiling of a berbamine derivative for lymphoma treatment
- vitro+vivo, lymphoma, NA
CaMKII ↓, TumCG↓, cMyc↓, ROS↑, UPR↑, ER Stress↑, PERK↑, BioAv↑, toxicity↓,
5543- BBM,    Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo
- in-vivo, Lung, B16-F10 - vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-231
BioAv↓, Half-Life↓, eff↑, TumMeta↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, MMP2↓, MMP9↓, VEGF↓, Bcl-2↓, eff↑, EPR↑,
5544- BBM,    Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca2+ axis
- in-vitro, AML, THP1
ROS↑, Ca+2↑,
5546- BBM,    Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II
- vitro+vivo, Liver, NA
TumCP↓, CaMKII ↓,
5555- BBM,    Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells
- vitro+vivo, RCC, NA
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, toxicity↓, FTO↑,
5556- BBM,    Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells
- in-vitro, Melanoma, NA
TumCP↓, eff↑, TumCCA↑, IKKα↓, p65↓, Bcl-xL↓, BID↓, survivin↓,
5547- BBM,    Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway
- in-vitro, CRC, HT29
tumCV↓, selectivity↑, Casp3↑, Casp9↑, Bax:Bcl2↑, ATG5↑, Beclin-1↑, TumCP↓, MEK↓, ERK↓,
5549- BBM,    Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells
- in-vitro, GBM, NA
eff?, tumCV↓, TumCG↓, ROS↑, P53↑, CSCs↓, CD133↓, ALDH1A1↓, Nanog↓, SOX2↓, OCT4↓, CDK1↓, CaMKII ↓, STAT3↓, Akt↓, ERK↓,
5550- BBM,  docx,  Chit,    Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities
- in-vivo, Var, NA
eff↑, BioAv↑, Apoptosis↑, survivin↓,
5551- BBM,    Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis
- vitro+vivo, Bladder, NA
tumCV↓, TumCP↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, EMT↓, TumMeta↓, p65↓, p‑p65↓, IKKα↓, NF-kB↑, ROS↑, NRF2↓, HO-1↓, SOD2↓, GPx1↓, Bax:Bcl2↑, TumVol↓,
5552- BBM,    Effects of berbamine against myocardial ischemia/reperfusion injury: Activation of the 5' adenosine monophosphate‐activated protein kinase/nuclear factor erythroid 2‐related factor pathway and changes in the mitochondrial state
- in-vivo, Stroke, NA
*eff↑, *ROS↓, *mtDam↓, *AMPK↑, *NRF2↑, *NADPH↑, *HO-1↑, *cardioP↑,
5553- BBM,    A review on berbamine–a potential anticancer drug
- Review, Var, NA
P-gp↓, MDR1↓, survivin↓, NF-kB↓, TumCP↓, TumCCA↑, Apoptosis↑, SMAD3↑, P21↑, cycD1/CCND1↓, cMyc↑, Bcl-2↓, Bcl-xL↓, BAX↑, CaMKII ↓, ChemoSen↑, MMP2↓, MMP9↓, TIMP1↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, cl‑PARP↑, IL6↓, ROS↑,
5548- BBR,    Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway
- in-vitro, HCC, SMMC-7721 cell
TumCG↓, Apoptosis↑, Cyt‑c↑, BAX↑, P53↑, Bcl-2↓, survivin↓,
5545- BBR,    Improving the oral bioavailability of berberine: A crystal engineering approach
- in-vivo, Nor, NA
BioAv↑,
5182- BBR,    Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9
- in-vitro, SCC, SCC4
TumCMig↓, TumCI↓, p‑JNK↝, p‑ERK↝, p‑p38↝, IKKα↝, NF-kB↝, MMP2↓, MMP9↓,
4274- BBR,    Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway
- in-vivo, NA, NA
*IL1β↓, *IL6↓, *TNF-α↓, *CRP↓, *CREB↑, *BDNF↑,
4275- BBR,    Pharmacological effects of berberine on mood disorders
- Review, NA, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *eff↑, *5HT↑, *Mood↑, *BDNF↑,
4298- BBR,    Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance
- in-vivo, AD, NA
*cognitive↑, *p‑tau↓, *GSK‐3β↓, *PP2A↑, *memory↑, *Akt↑, *LC3II↑, *Beclin-1↑,
4299- BBR,    Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-κB signaling, oxidative stress and neuroinflammation
- in-vivo, AD, NA
*memory↑, *p‑tau↓, *NF-kB↓, *GSH↑, *lipid-P↓, *cognitive↑, *ROS↓, *Inflam↓,
4300- BBR,    Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis
- Review, AD, NA
*APP↓, *cognitive↑, *Aβ↓, *BACE↓, *tau?,
4340- BBR,    Agonist-dependent differential effects of berberine in human platelet aggregation
- Human, NA, NA
*AntiAg↑, *other?,
4658- BBR,    Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
CSCs↓, TumCP↓, cycD1/CCND1↓, p27↑, P21↑, TumCCA↑, Apoptosis↑, ChemoSen↑, β-catenin/ZEB1↓, FTO↑, CD44↓, CD133↓, ChemoSen↑,
5181- BBR,  Cisplatin,    Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
tumCV↓, MDR1↓, ChemoSen↑, PI3K↓, Akt↓, mTOR↓,
5179- BBR,    Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy
- Review, Var, NA
AMPK↑, Casp3↑, cl‑PARP↑, Mcl-1↓, cFLIP↓, β-catenin/ZEB1↓, Wnt↓, STAT3↓, mTOR↓, Hif1a↓, NF-kB↓, SIRT1↑, DNMT1↓, DNMT3A↓, miR-29b↓, IGFBP1↑, eff↑, chemoPv↑, BioAv↓,
5178- BBR,    Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, Apoptosis↑, Bax:Bcl2↑, MMP↓, Casp9↑, Casp3↑, PARP↑, DNAdam↑, selectivity↑, Cyt‑c↑,
5177- BBR,    Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway
- in-vitro, Oral, HMC3
TumCCA↑, Apoptosis↑, TumCG↓, Casp3↑, TumCCA↑, ROS↑, Ca+2↑, MMP↓, ER Stress↑, Cyt‑c↑,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
5176- BBR,    Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice
- vitro+vivo, CRC, HCT116 - in-vitro, CRC, SW480 - in-vitro, CRC, LoVo
TumVol↓, Ki-67↓, COX2↓, AMPK↑, mTOR↓, NF-kB↓, cycD1/CCND1↓, survivin↓, P53↑, cl‑Casp3↑, TumCP↓, Inflam↓, COX2↓, ACC↑,
6424- BBR,    Berberine Protects Glomerular Podocytes via Inhibiting Drp1-Mediated Mitochondrial Fission and Dysfunction
- in-vivo, Nor, NA
*mt-ROS↓, *DRP1/DNM1L↓,
6764- BBR,    Berberine as a therapeutic alkaloid against ESKAPE and multiple drug-resistant bacteria: a comprehensive review
- Review, Nor, NA
*AntiBio↑, *BioAv↓,
1030- BBR,    Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
- in-vitro, Lung, H460
PD-L1↓, TumCG↓, Ki-67↓, cl‑Casp3↑,
1092- BBR,    Berberine as a Potential Anticancer Agent: A Comprehensive Review
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumAuto↑, TumCI↓, IL1↓, IL6↓, TNF-α↓, LDH↓, P2X7↓, proCasp1↓, Casp1↓, ASC↓,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
1010- BBR,    Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells
- vitro+vivo, CRC, NA
β-catenin/ZEB1↓, TumCG↓,
7- BBR,    Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth
- vitro+vivo, MB, LS174T
HH↓, Gli1∅, PTCH1↓, Smo↓, TumCG↓,
932- BBR,    The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity
- in-vivo, Nor, NA
*glucoNG↓, *Glycolysis↑, *NH3↑, *NADPH/NADP+↑, *ATP↓, *toxicity↑,
956- BBR,    Berberine inhibits HIF-1alpha expression via enhanced proteolysis
- in-vitro, Nor, HUVECs - in-vitro, GC, SCM1
Hif1a↓, angioG↓,

Showing Research Papers: 1201 to 1250 of 7372
Prev Page 25 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7372

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GPx1↓, 2,   HO-1↓, 2,   NRF2↓, 2,   ROS?, 1,   ROS↑, 10,   SOD2↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   MEK↓, 2,   MMP↓, 4,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   ACC↑, 1,   AMPK↑, 2,   cMyc↓, 2,   cMyc↑, 1,   cMyc↝, 1,   LDH?, 1,   LDH↓, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 1,   Apoptosis↑, 13,   BAX↑, 5,   Bax:Bcl2↑, 3,   Bcl-2↓, 6,   Bcl-xL↓, 2,   BID↓, 1,   BID↑, 1,   cl‑Casp↑, 1,   Casp1↓, 1,   proCasp1↓, 1,   Casp3↑, 7,   cl‑Casp3↑, 3,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 4,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Chk2↑, 1,   Cyt‑c↑, 5,   DR4↑, 1,   DR5↑, 1,   FasL↑, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   IAP2↓, 1,   p‑JNK↝, 1,   Mcl-1↓, 1,   MDM2↓, 1,   p27↑, 3,   P2X7↓, 1,   p‑p38↝, 1,   survivin↓, 5,   TRAIL↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 6,   p‑CaMKII ↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

BRD4↓, 1,   tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 2,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   BNIP3?, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   DNAdam↑, 2,   DNMT1↓, 1,   DNMT3A↓, 1,   P53↑, 4,   PARP↑, 2,   cl‑PARP↑, 3,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

BRD4↓, 1,   CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 6,   cycE/CCNE↓, 1,   P21↑, 4,   TFAP2A↓, 1,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD133↓, 2,   CD44↓, 1,   CSCs↓, 2,   EMT↓, 2,   ERK↓, 3,   p‑ERK↓, 1,   p‑ERK↝, 1,   Gli1∅, 1,   HH↓, 1,   IGFBP1↑, 1,   mTOR↓, 3,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 3,   p‑PI3K↓, 1,   PTCH1↓, 1,   Smo↓, 1,   SOX2↓, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   TumCG↓, 12,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   E-cadherin↑, 1,   FTO↑, 2,   Ki-67↓, 2,   miR-29b↓, 1,   MMP2↓, 3,   MMP9↓, 3,   N-cadherin↓, 1,   Smad1↑, 1,   SMAD3↑, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TumCI↓, 6,   TumCMig↓, 6,   TumCP↓, 12,   TumCP↑, 1,   TumMeta↓, 3,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EPR↑, 1,   Hif1a↓, 3,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   COX2↓, 3,   IKKα↓, 3,   IKKα↝, 1,   IL1↓, 1,   IL6↓, 2,   Inflam↓, 1,   JAK↝, 1,   NF-kB↓, 5,   NF-kB↑, 1,   NF-kB↝, 1,   p65↓, 2,   p‑p65↓, 1,   PD-L1↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   ChemoSen↑, 6,   Dose∅, 2,   eff?, 1,   eff↓, 3,   eff↑, 5,   Half-Life↓, 1,   MDR1↓, 2,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 2,   LDH?, 1,   LDH↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   toxicity↓, 2,   TumVol↓, 2,   TumVol↑, 1,  
Total Targets: 170

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NADPH/NADP+↑, 1,   NRF2↑, 1,   ROS↓, 3,   mt-ROS↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   DRP1/DNM1L↓, 1,   mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   CREB↑, 1,   glucoNG↓, 1,   Glycolysis↑, 1,   NADPH↑, 1,   NH3↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   iNOS↓, 1,   p‑JNK↓, 1,   p‑MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↓, 1,   GSK‐3β↓, 1,   p‑STAT1↓, 1,   p‑STAT3↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   APP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL1β↓, 2,   IL6↓, 2,   Inflam↓, 2,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   Macrophages↓, 1,   Neut↓, 1,   NF-kB↓, 1,   p‑NF-kB↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   BDNF↑, 2,   tau?, 1,   p‑tau↓, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,   PP2A↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 2,   Mood↑, 1,   toxicity↑, 1,  
Total Targets: 60

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page